With the development of anticancer strategies, targeted therapies using BRAF and MEK inhibitors as well as immunotherapies with the use of immune check point inhibitors, like cytotoxic T lymphocyte-associated antigens 4 (CTLA-4), programmed cell death 1 (PD-1), PD ligand 1 (PDL-1) and lymphocyte-activation gene 3 (LAG3), have been included in the fight against melanoma [6,7]. Here, LAG3 is linked to melanoma.